

Paul V Browne

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/148305/paul-v-browne-publications-by-year.pdf>

Version: 2024-04-23

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

45
papers

2,737
citations

19
h-index

48
g-index

48
ext. papers

3,122
ext. citations

7.3
avg, IF

4.23
L-index

#	Paper	IF	Citations
45	Severe COVID-19 is characterised by inflammation and immature myeloid cells early in disease progression.. <i>Heliyon</i> , 2022 , 8, e09230	3.6	1
44	Examining the Usefulness of the Charlson Comorbidity Index to Predict Early Mortality in Patients with Acute Myeloid Leukaemia. <i>Blood</i> , 2021 , 138, 1218-1218	2.2	
43	A novel aryl-guanidinium derivative, VP79s, targets the signal transducer and activator of transcription 3 signaling pathway, downregulates myeloid cell leukaemia-1 and exhibits preclinical activity against multiple myeloma.. <i>Life Sciences</i> , 2021 , 290, 120236	6.8	
42	IgD Subtype But Not IgM or Non-Secretory Is a Prognostic Marker for Poor Survival Following Autologous Hematopoietic Cell Transplantation in Multiple Myeloma. Results From the EBMT CALM (Collaboration to Collect Autologous Transplant Outcomes in Lymphomas and Myeloma) Study. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021 , 21, 686-693	2	1
41	More on COVID-19 coagulopathy in Caucasian patients. <i>British Journal of Haematology</i> , 2020 , 189, 1060-1061	10.51	51
40	COVID19 coagulopathy in Caucasian patients. <i>British Journal of Haematology</i> , 2020 , 189, 1044-1049	4.5	226
39	A Novel Aryl-Guanidinium Based Compound Targets the STAT3 Signalling Pathway, Downregulates MCL-1 Expression and Induces Anti-Myeloma Activity. <i>Blood</i> , 2020 , 136, 35-36	2.2	
38	Ibrutinib as a salvage therapy after allogeneic HCT for chronic lymphocytic leukemia. <i>Bone Marrow Transplantation</i> , 2020 , 55, 884-890	4.4	9
37	Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Acute Lymphoblastic Leukemia and Karnofsky Performance Status Score Equal or Lower Than 80%. a Study from the Acute Leukemia Working Party (ALWP) of the European Society for Blood and Marrow	2.2	
36	The Impact of Advanced Patient Age on Mortality after Allogeneic Hematopoietic Cell Transplantation for Non-Hodgkin Lymphoma: A Retrospective Study by the European Society for Blood and Marrow Transplantation Lymphoma Working Party. <i>Biology of Blood and Marrow Transplantation</i> , 2019 , 25, 86-93	4.7	16
35	Incidence of Second Primary Malignancies after Autologous Transplantation for Multiple Myeloma in the Era of Novel Agents. <i>Biology of Blood and Marrow Transplantation</i> , 2018 , 24, 930-936	4.7	9
34	Melphalan 140 mg/m or 200 mg/m for autologous transplantation in myeloma: results from the Collaboration to Collect Autologous Transplant Outcomes in Lymphoma and Myeloma (CALM) study. A report by the EBMT Chronic Malignancies Working Party. <i>Haematologica</i> , 2018 , 103, 514-521	6.6	39
33	Conception and Pregnancy Outcomes after Haematopoietic Stem Cell Transplant: A Retrospective Study from the Transplant Complications Working Party of the European Society for Blood and Marrow Transplantation. <i>Blood</i> , 2018 , 132, 2139-2139	2.2	3
32	Improving results of allogeneic hematopoietic cell transplantation for adults with acute lymphoblastic leukemia in first complete remission: an analysis from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. <i>Haematologica</i> , 2017 , 102, 139-149	6.6	65
31	Retinoic acid induction of CD1d expression primes chronic lymphocytic leukemia B cells for killing by CD8 invariant natural killer T cells. <i>Clinical Immunology</i> , 2017 , 183, 91-98	9	13
30	Long-Term Outcome of Allogeneic Stem Cell Transplantation (allo-SCT) in Patients with Waldenstrom Macroglobulinemia (WM)-a Retrospective Study of the Lymphoma Working Party of the European Society for Blood and Marrow Transplantation (EBMT). <i>Blood</i> , 2016 , 128, 4661-4661	2.2	1
29	An EBMT Prospective Non-Interventional Study of Outcomes and Toxicity of Allogeneic Stem Cell Transplantation in Chronic Myeloid Leukemia Patients Previously Treated with Second Generation Tyrosine Kinase Inhibitors. <i>Blood</i> , 2016 , 128, 628-628	2.2	1

28	Association of Macroeconomic Factors With Nonrelapse Mortality After Allogeneic Hematopoietic Cell Transplantation for Adults With Acute Lymphoblastic Leukemia: An Analysis From the Acute Leukemia Working Party of the EBMT. <i>Oncologist</i> , 2016 , 21, 377-83	5.7	7
27	Immune thrombocytopenia purpura associated with multiple myeloma. <i>Annals of Hematology</i> , 2016 , 95, 1371-2	3	4
26	Allogeneic Hematopoietic Cell Transplantation (HCT) for Advanced Mycosis Fungoides and Sezary Syndrome (MF/SS): Impact of Increasing the Use of Unrelated Donors (UD) - the EBMT Lymphoma Working Party Experience. <i>Blood</i> , 2015 , 126, 4403-4403	2.2	
25	Chronic myeloid leukaemia presenting post-radiotherapy for prostate cancer: further evidence for an immunosurveillance effect. <i>British Journal of Haematology</i> , 2013 , 162, 708-10	4.5	2
24	Long-term safety and efficacy of sustained eculizumab treatment in patients with paroxysmal nocturnal haemoglobinuria. <i>British Journal of Haematology</i> , 2013 , 162, 62-73	4.5	253
23	The microtubule targeting agent PBOX-15 inhibits integrin-mediated cell adhesion and induces apoptosis in acute lymphoblastic leukaemia cells. <i>International Journal of Oncology</i> , 2013 , 42, 239-46	4.4	10
22	Association Of Health Care Expenditure With Results Of Allogeneic HSCT For Adults With ALL: An Analysis From Acute Leukemia Working Party Of The EBMT. <i>Blood</i> , 2013 , 122, 2150-2150	2.2	
21	Incidence of the BRAF V600E mutation in chronic lymphocytic leukaemia and prolymphocytic leukaemia. <i>Leukemia Research</i> , 2012 , 36, 483-4	2.7	26
20	Myeloma Genetics International Consortium. <i>Leukemia and Lymphoma</i> , 2012 , 53, 796-800	1.9	7
19	Genetic variation at the 8q24 locus confers risk to multiple myeloma. <i>British Journal of Haematology</i> , 2012 , 156, 133-6	4.5	4
18	Large granular lymphocyte leukemia: natural history and response to treatment. <i>Leukemia and Lymphoma</i> , 2010 , 51, 839-45	1.9	25
17	T-lymphoblastic leukemia/lymphoma: a single center retrospective study of outcome. <i>Leukemia and Lymphoma</i> , 2010 , 51, 1035-9	1.9	6
16	A novel RUNX1 mutation in a kindred with familial platelet disorder with propensity to acute myeloid leukaemia: male predominance of affected individuals. <i>European Journal of Haematology</i> , 2010 , 85, 552-3	3.8	12
15	Long-term effect of the complement inhibitor eculizumab on kidney function in patients with paroxysmal nocturnal hemoglobinuria. <i>American Journal of Hematology</i> , 2010 , 85, 553-9	7.1	138
14	Insulin-Like Growth Factor Binding Protein-3 (IGFBP3) Gene Expression In Myeloma Cell Lines and Patients. <i>Blood</i> , 2010 , 116, 2489-2489	2.2	
13	Minimal residual disease detection in childhood acute lymphoblastic leukaemia patients at multiple time-points reveals high levels of concordance between molecular and immunophenotypic approaches. <i>British Journal of Haematology</i> , 2009 , 144, 107-15	4.5	47
12	The novel tubulin-targeting agent pyrrolo-1,5-benzoxazepine-15 induces apoptosis in poor prognostic subgroups of chronic lymphocytic leukemia. <i>Cancer Research</i> , 2009 , 69, 8366-75	10.1	26
11	Genetic variants in XRR5 may predict development of venous thrombotic events in myeloma patients on thalidomide. <i>Blood</i> , 2009 , 113, 5691-2	2.2	5

10	Eculizumab, a terminal complement inhibitor, improves anaemia in patients with paroxysmal nocturnal haemoglobinuria. <i>British Journal of Haematology</i> , 2008 , 142, 263-72	4.5	37
9	Variation in DNA repair genes XRCC3, XRCC4, XRCC5 and susceptibility to myeloma. <i>Human Molecular Genetics</i> , 2007 , 16, 3117-27	5.6	47
8	High Incidence of Progression to Chronic Renal Insufficiency in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH).. <i>Blood</i> , 2007 , 110, 3678-3678	2.2	3
7	CD38 expression level and pattern of expression remains a reliable and robust marker of progressive disease in chronic lymphocytic leukemia. <i>Leukemia and Lymphoma</i> , 2006 , 47, 2371-9	1.9	26
6	The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria. <i>New England Journal of Medicine</i> , 2006 , 355, 1233-43	59.2	839
5	A novel technique for culture of human dermal microvascular endothelial cells under either serum-free or serum-supplemented conditions: isolation by panning and stimulation with vascular endothelial growth factor. <i>Experimental Cell Research</i> , 1997 , 230, 244-51	4.2	74
4	Circulating activated endothelial cells in sickle cell anemia. <i>New England Journal of Medicine</i> , 1997 , 337, 1584-90	59.2	543
3	CD36-positive stress reticulocytosis in sickle cell anemia. <i>Translational Research</i> , 1996 , 127, 340-7		39
2	Disturbance of plasma and platelet thrombospondin levels in sickle cell disease. <i>American Journal of Hematology</i> , 1996 , 51, 296-301	7.1	71
1	Donor-cell leukemia after bone marrow transplantation for severe aplastic anemia. <i>New England Journal of Medicine</i> , 1991 , 325, 710-3	59.2	51